European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

by Marie Weil
January 25, 2023
A A
Share on LinkedinShare on Twitter
  • Sandoz plans to acquire worldwide product rights for Mycamine®(micafungin sodium) from Astellas
  • Acquiring leading global echinocandin, one of three major antifungal classes, will significantly reinforce Sandoz hospital offering and leading anti-infectives portfolio
  • Addition of Mycamine®will support Sandoz global program to combat antimicrobial resistance (AMR) by targeted use of most appropriate therapies 

Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas.

Closing is anticipated in the course of H1, 2023, subject to standard conditions and regulatory approvals.

Astellas reported Mycamine® sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2022. The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2021.

Sandoz CEO Richard Saynor said: “Acquiring this leading and respected global brand will significantly reinforce the Sandoz global hospital offering, as well as complement our existing global leadership position in generic antibiotics.”

He added: “This will also be an important addition to our growing portfolio of anti-infective therapies aimed at combatting the spread of antimicrobial resistance, by providing the right drug to the right patient at the right time.”

Sandoz Anti-Infectives global medical lead Nicholas Adomakoh said: “Modern medicine is increasingly characterized by the need for complex interventions involving highly vulnerable patients. This welcome and timely portfolio addition will allow us to respond even better to the needs of patients and clinicians across the healthcare continuum.”

Mycamine®   is a leading global echinocandin, one of three major classes of antifungal agents, with a global patient base of well over two million. It   is a therapy of choice in hospitals and intensive care units worldwide, a proven prophylactic in hematology and oncology patients, and widely used in organ transplants.

Mycamine®   is indicated for treatment of invasive candidiasis and espophageal candidiasis, which are currently both on the rise with a higher occurrence of associated hospital outbreaks, as well as prevention of candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.

Tags: < Invest

Related Industries

Health

Interview with Mr. Sébastien Huron, CEO, Virbac group

March 6, 2023
Health

Bayer driving innovation in radiology with new research across the portfolio presented at ECR

February 23, 2023
Health

Philips recognized as top innovator for 10th consecutive year

February 17, 2023
Health

Bayer completes acquisition of Blackford Analysis Ltd.

February 14, 2023
Health

Aleksandra Rizo Appointed as CEO of Vividion Therapeutics

January 25, 2023
Health


Philips and Masimo expand partnership to improve telehealth for patients and clinicians around the world

January 19, 2023

European Corporate Development & Strategy Awards

March 9, 2023

...

UBS to acquire Credit Suisse

March 20, 2023

...

Xiaomi Begins Product Carbon Footprint Assessment and Champions Sustainable Living Awareness

February 27, 2023

...

Carrier Makes Donation to the European Food Banks Federation to Help Reduce Food Insecurity in Europe

March 8, 2023

...

Efficient and high-performing vehicle architecture: Cooperation of Continental and Infineon

March 14, 2023

...

default

Voith Hydro opens new center of competence for generator components

March 8, 2023

...

Interview with Mr. Sébastien Huron, CEO, Virbac group

March 6, 2023

...

Thierry Koskas Is Appointed Citroën Brand CEO and Stellantis Chief Sales & Marketing Officer

February 24, 2023

...

Infineon and UMC extend automotive partnership with long-term agreement for 40nm eNVM microcontroller production

March 8, 2023

...

BASF advances innovation pipeline with integrated solutions to accelerate agriculture’s transformation

March 16, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist